Inventor · disambiguated record
Yasuhiro Fujino
Also filed as: FUJINO YASUHIRO
7 granted patents·2 pending applications·90 citations·filing 1987–2019
82Inventor score
Top patents by PatentIndex Score
9 records- 0191US9758578B2Human anti-IL-33 neutralizing monoclonal antibodyMITSUBISHI TANABE PHARMA CORP·Filed 2014·Granted Sep 12, 2017·15 cites·20 claims
- 0276US4835705AInterconnection area decision processorMITSUBISHI ELECTRIC CORP·Filed 1987·Granted May 30, 1989·68 cites·7 claims
- 0369US11725049B2Human anti-IL-33 neutralizing monoclonal antibodyMITSUBISHI TANABE PHARMA CORP·Filed 2019·Granted Aug 15, 2023·0 cites·23 claims
- 0467US7397269B2Disconnection and short detecting circuit that can detect disconnection and short of a signal line transmitting a differential clock signalRENESAS TECH CORP·Filed 2007·Granted Jul 8, 2008·5 cites·4 claims
- 0556US2017283494A1Human anti-il-33 neutralizing monoclonal antibodyMITSUBISHI TANABE PHARMA CORP·Filed 2017·Application pending·0 cites
- 0648US2018017573A1Polynucleotide construct capable of displaying fab in a cell-free translation system, and method for manufacturing and screening fab using sameMITSUBISHI TANABE PHARMA CORP·Filed 2017·Application pending·0 cites
- 0747US9753040B2Polynucleotide construct capable of displaying fab in a cell-free translation system, and method for manufacturing and screening fab using sameFUJINO YASUHIRO·Filed 2011·Granted Sep 5, 2017·0 cites·23 claims
- 0843US7212027B2Disconnection and short detecting circuit that can detect disconnection and short of a signal line transmitting a differential clock signalRENESAS TECH CORP·Filed 2004·Granted May 1, 2007·2 cites·16 claims
- 0939US7928126B2Cyanopyridine derivative and use thereof as medicineMITSUBISHI TANABE PHARMA CORP·Filed 2006·Granted Apr 19, 2011·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Yasuhiro Fujino files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →